Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma.
Cetuximab
EGFR
ErbB receptors
head and neck squamous cell carcinoma
immune checkpoint inhibitors
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
10
2022
accepted:
13
01
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type, has often an aggressive course and is poorly responsive to current therapeutic approaches, so that 5-year survival rates for patients diagnosed with advanced disease is lower than 50%. The Epidermal Growth Factor Receptor (EGFR) has emerged as an established oncogene in HNSCC. Indeed, although HNSCCs are a heterogeneous group of cancers which differ for histological, molecular and clinical features, EGFR is overexpressed or mutated in a percentage of cases up to about 90%. Moreover, aberrant expression of the other members of the ErbB receptor family, ErbB2, ErbB3 and ErbB4, has also been reported in variable proportions of HNSCCs. Therefore, an increased expression/activity of one or multiple ErbB receptors is found in the vast majority of patients with HNSCC. While aberrant ErbB signaling has long been known to play a critical role in tumor growth, angiogenesis, invasion, metastatization and resistance to therapy, more recent evidence has revealed its impact on other features of cancer cells' biology, such as the ability to evade antitumor immunity. In this paper we will review recent findings on how ErbB receptors expression and activity, including that associated with non-canonical signaling mechanisms, impacts on prognosis and therapy of HNSCC.
Identifiants
pubmed: 36817764
doi: 10.3389/fmed.2023.1066021
pmc: PMC9932042
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1066021Informations de copyright
Copyright © 2023 Palumbo, Benvenuto, Focaccetti, Albonici, Cifaldi, Rufini, Nardozi, Angiolini, Bei, Masuelli and Bei.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oral Oncol. 2014 May;50(5):513-9
pubmed: 24565983
Invest New Drugs. 2015 Aug;33(4):895-900
pubmed: 25937431
Ann Surg Oncol. 2008 Apr;15(4):1193-201
pubmed: 18172732
Lancet Oncol. 2013 Jul;14(8):697-710
pubmed: 23746666
Nat Med. 2016 Jun;22(6):624-31
pubmed: 27135741
PLoS One. 2020 Feb 18;15(2):e0229077
pubmed: 32069320
Strahlenther Onkol. 2013 Mar;189(3):202-14
pubmed: 23400686
Nat Rev Cancer. 2021 Mar;21(3):181-197
pubmed: 33462501
Cancer Cell. 2004 May;5(5):489-500
pubmed: 15144956
Cancer Med. 2021 Oct;10(20):7012-7020
pubmed: 34528763
Cell Death Dis. 2019 Jul 15;10(8):540
pubmed: 31308358
Otolaryngol Head Neck Surg. 2009 Oct;141(4):467-73
pubmed: 19786214
Lancet Oncol. 2015 Feb;16(2):221-32
pubmed: 25596659
Clin Cancer Res. 2022 Apr 14;28(8):1560-1571
pubmed: 35046059
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Clin Transl Oncol. 2016 Jun;18(6):592-8
pubmed: 26459251
Lancet Oncol. 2021 Jun;22(6):883-892
pubmed: 33989559
World J Surg Oncol. 2018 Jun 28;16(1):118
pubmed: 29954411
Head Neck. 2021 Jul;43(7):1983-1994
pubmed: 33660372
Oral Oncol. 2021 Sep;120:105420
pubmed: 34218062
Appl Immunohistochem Mol Morphol. 2021 Sep 1;29(8):576-584
pubmed: 33758141
Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1230-7
pubmed: 21467228
Acta Otolaryngol. 2019 Oct;139(10):913-917
pubmed: 31430224
Appl Immunohistochem Mol Morphol. 2014 Oct;22(9):674-80
pubmed: 25279714
Front Cell Dev Biol. 2016 Aug 22;4:88
pubmed: 27597943
Cancer Metastasis Rev. 2017 Sep;36(3):463-473
pubmed: 28866730
Med Oncol. 2021 Mar 8;38(4):35
pubmed: 33683482
Clin Cancer Res. 2013 Apr 1;19(7):1858-72
pubmed: 23444227
Oral Oncol. 2015 Jan;51(1):12-5
pubmed: 25459157
Pharmacol Rev. 2022 Jan;74(1):18-47
pubmed: 34987087
Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1486-92
pubmed: 18559565
Clin Exp Metastasis. 2014 Mar;31(3):307-16
pubmed: 24338375
Front Pharmacol. 2017 Jun 19;8:382
pubmed: 28674498
J Oral Pathol Med. 2015 Nov;44(10):818-22
pubmed: 25581523
J Cell Physiol. 2012 Sep;227(9):3344-53
pubmed: 22213373
Oral Oncol. 2008 Mar;44(3):227-35
pubmed: 17604679
Oral Oncol. 2018 Nov;86:251-257
pubmed: 30409309
JAMA Otolaryngol Head Neck Surg. 2016 Jun 1;142(6):559-67
pubmed: 27077364
Rhinology. 2020 Aug 1;58(4):368-376
pubmed: 32199023
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Cancers Head Neck. 2017 Jan 18;2:2
pubmed: 31093349
Oral Oncol. 2018 Feb;77:83-89
pubmed: 29362129
Head Neck. 2016 Apr;38 Suppl 1:E1625-38
pubmed: 26614708
Neoplasma. 2012;59(5):508-15
pubmed: 22668015
Sci Rep. 2019 Sep 19;9(1):13564
pubmed: 31537844
Am J Cancer Res. 2015 Sep 15;5(10):2944-58
pubmed: 26693051
Mol Cancer Ther. 2019 Nov;18(11):1909-1915
pubmed: 31676542
Mol Cancer. 2019 Mar 30;18(1):63
pubmed: 30927923
Front Cell Dev Biol. 2020 Aug 17;8:732
pubmed: 33015030
Hum Gene Ther Clin Dev. 2013 Sep;24(3):134-42
pubmed: 24099518
Cancer Biol Ther. 2010 Mar 1;9(5):343-9
pubmed: 20448462
Cancers (Basel). 2021 Jul 15;13(14):
pubmed: 34298761
Pathol Res Pract. 2015 Oct;211(10):776-81
pubmed: 26296920
Semin Cancer Biol. 2021 Jul;72:65-75
pubmed: 31698088
Pharmacol Res. 2014 Jan;79:34-74
pubmed: 24269963
Eur J Cancer. 2010 Apr;46(6):1144-52
pubmed: 20149638
Front Genet. 2015 Feb 04;6:17
pubmed: 25699077
Pol J Pathol. 2021;72(4):296-314
pubmed: 35142162
Adv Immunol. 2016;130:25-74
pubmed: 26922999
Eur J Cancer. 2013 Apr;49(6):1161-8
pubmed: 23265711
J Clin Oncol. 2015 Dec 10;33(35):4202-9
pubmed: 26527790
Cancer. 2015 Oct 15;121(20):3600-11
pubmed: 26195293
Anticancer Res. 2018 Feb;38(2):795-802
pubmed: 29374704
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Acta Otolaryngol. 2012 Sep;132(9):1006-12
pubmed: 22667340
J Pathol. 2001 Oct;195(3):343-8
pubmed: 11673832
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Radiother Oncol. 2011 Jun;99(3):331-8
pubmed: 21719137
Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):331-8
pubmed: 20732768
Eur J Cancer. 2020 Dec;141:21-29
pubmed: 33125944
Oral Oncol. 2021 Jan;112:105074
pubmed: 33142224
Oncotarget. 2017 May 16;8(20):32668-32682
pubmed: 28427242
Cancer Treat Res Commun. 2022;33:100649
pubmed: 36279709
Histopathology. 2013 Aug;63(2):271-8
pubmed: 23763474
Sci Rep. 2021 Sep 24;11(1):19051
pubmed: 34561494
PLoS One. 2015 Feb 06;10(2):e0117781
pubmed: 25658924
Hum Gene Ther. 2021 Feb;32(3-4):150-157
pubmed: 33349123
Front Oncol. 2019 Oct 15;9:1084
pubmed: 31681613
Cancer Res. 2017 Mar 1;77(5):1188-1199
pubmed: 28031227
Onco Targets Ther. 2022 Apr 08;15:353-359
pubmed: 35422629
PLoS One. 2018 Aug 23;13(8):e0202790
pubmed: 30138436
Cancer Sci. 2019 Jul;110(7):2119-2132
pubmed: 31141251
Curr Opin Immunol. 2017 Apr;45:52-59
pubmed: 28208102
Ann Oncol. 2011 May;22(5):1078-1087
pubmed: 21048039
Crit Rev Oncol Hematol. 2017 Mar;111:39-51
pubmed: 28259294
Cancer Invest. 2010 Jun;28(5):495-500
pubmed: 20014947
Clin Cancer Res. 2015 Feb 15;21(4):870-81
pubmed: 25492084
Cancers (Basel). 2020 Oct 30;12(11):
pubmed: 33143170
J Natl Cancer Inst. 2019 Dec 1;111(12):1339-1349
pubmed: 30863843
Methods Mol Biol. 2017;1652:3-35
pubmed: 28791631
Int J Mol Sci. 2022 Mar 30;23(7):
pubmed: 35409179
Eur J Cancer. 2013 May;49(7):1609-18
pubmed: 23265705
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Sep;122(3):313-21
pubmed: 27444519
Mol Cancer. 2021 Jan 18;20(1):17
pubmed: 33461557
Clin Cancer Res. 2022 Apr 1;28(7):1335-1344
pubmed: 35091445
J Transl Med. 2011 Oct 04;9:168
pubmed: 21970318
Int J Oral Maxillofac Surg. 2018 Jul;47(7):817-823
pubmed: 29395668
Cancer. 2020 May 15;126(10):2146-2152
pubmed: 32073648
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1267-1272
pubmed: 30017201
Eur J Cancer. 2010 Jul;46(11):2088-96
pubmed: 20537890
Oncotarget. 2014 Aug 15;5(15):5934-49
pubmed: 25153719
Ann Oncol. 2012 Apr;23(4):1016-22
pubmed: 21865152
Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Apr;129(4):377-387
pubmed: 32081558
Onco Targets Ther. 2017 Mar 13;10:1527-1533
pubmed: 28352186
Cancers (Basel). 2021 Nov 19;13(22):
pubmed: 34830956
Oncogene. 1999 Feb 11;18(6):1267-75
pubmed: 10022808
Brief Funct Genomics. 2019 Mar 22;18(2):133-139
pubmed: 30137232
Radiother Oncol. 2010 Nov;97(2):330-7
pubmed: 20667610
Mol Cancer Ther. 2018 Mar;17(3):710-716
pubmed: 29440293
Clin Cancer Res. 2005 Aug 15;11(16):5856-62
pubmed: 16115926
BMC Cancer. 2017 Sep 12;17(1):646
pubmed: 28899363
Life (Basel). 2022 May 20;12(5):
pubmed: 35629423
Clin Cancer Res. 2015 Oct 15;21(20):4597-606
pubmed: 26138066
Radiother Oncol. 2013 Sep;108(3):489-94
pubmed: 24060179
Ann Oncol. 2017 Nov 01;28(11):2827-2835
pubmed: 28950289
Front Biosci (Landmark Ed). 2011 Jan 01;16(3):1060-8
pubmed: 21196218
Mod Pathol. 2021 Nov;34(11):1966-1978
pubmed: 34218257
J Hematol Oncol. 2022 Jun 28;15(1):83
pubmed: 35765040
Clin Cancer Res. 2015 Feb 1;21(3):526-33
pubmed: 25424855
Front Pharmacol. 2016 Sep 26;7:327
pubmed: 27729860
Laryngoscope. 2012 Dec;122(12):2762-8
pubmed: 23086695
Radiother Oncol. 2022 Apr;169:64-70
pubmed: 35157978
Radiother Oncol. 2013 Sep;108(3):370-7
pubmed: 23830194
Front Oncol. 2019 May 20;9:383
pubmed: 31165040
In Vivo. 2017 01-02;31(1):23-34
pubmed: 28064216
Anticancer Res. 2013 Apr;33(4):1575-83
pubmed: 23564800
Otolaryngol Head Neck Surg. 2017 Aug;157(2):239-251
pubmed: 28397583
Autops Case Rep. 2021 Apr 15;11:e2021251
pubmed: 33968826
Cells. 2022 Sep 14;11(18):
pubmed: 36139440
Clin Cancer Res. 1999 Dec;5(12):4164-74
pubmed: 10632356
Med Oncol. 2017 Jun;34(6):107
pubmed: 28452036
J Oral Pathol Med. 2010 Jan;39(1):79-86
pubmed: 19691460
Clin Cancer Res. 2011 May 1;17(9):2947-54
pubmed: 21355076
Clin Cancer Res. 2011 Aug 1;17(15):5197-204
pubmed: 21653686
Crit Rev Oncol Hematol. 2021 Aug;164:103424
pubmed: 34245856
J Clin Oncol. 2014 Sep 20;32(27):2940-50
pubmed: 25154822
J Oral Pathol Med. 2014 Apr;43(4):304-8
pubmed: 24645976
Clin Cancer Res. 2009 Nov 1;15(21):6484-9
pubmed: 19861462
Cancer Chemother Pharmacol. 2015 Jul;76(1):13-20
pubmed: 25952795
Head Neck Pathol. 2021 Sep;15(3):743-756
pubmed: 33428063
Oncotarget. 2016 Nov 8;7(45):74362-74379
pubmed: 27556186
Eur J Cancer. 2011 Oct;47(15):2364-72
pubmed: 21852109
Laryngoscope. 2012 Aug;122(8):1724-33
pubmed: 22549618
J Biol Chem. 2016 Apr 15;291(16):8453-64
pubmed: 26895960
J Oral Pathol Med. 2015 Oct;44(9):734-45
pubmed: 25495427
J Oral Pathol Med. 2014 Mar;43(3):205-10
pubmed: 24020871
Head Neck Pathol. 2015 Sep;9(3):360-8
pubmed: 25563452
Eur J Cancer. 2018 Oct;102:52-68
pubmed: 30142511
Oral Oncol. 2012 Jan;48(1):67-72
pubmed: 21831696
Cancer J. 2022 Sep-Oct 01;28(5):346-353
pubmed: 36165722
J Pathol. 2004 Nov;204(3):317-25
pubmed: 15476268
Head Neck. 2021 May;43(5):1641-1651
pubmed: 33547683
J Transl Med. 2011 Jul 29;9:126
pubmed: 21801427
J Transl Med. 2021 Sep 27;19(1):408
pubmed: 34579737
J Natl Compr Canc Netw. 2017 Jun;15(6):761-770
pubmed: 28596256
Clin Cancer Res. 2006 Sep 1;12(17):5064-73
pubmed: 16951222
Clin Cancer Res. 2012 Apr 15;18(8):2278-89
pubmed: 22351687
Ann Transl Med. 2020 Mar;8(6):402
pubmed: 32355846
Oral Oncol. 2011 Jun;47(6):487-96
pubmed: 21498106
Oncoimmunology. 2020 Apr 7;9(1):1747732
pubmed: 32313730
Nutrients. 2020 May 14;12(5):
pubmed: 32423101